Merck & Co., Inc. (MRK) PEG Ratio: 1.81
Is Merck & Co., Inc.’s PEG ratio high or low?
Merck & Co., Inc.'s PEG ratio of 1.81 is 94% above its 4-year average of 0.93, near the high end of its 4-year range (0.00–1.81).
100.00% above its 12-month average of 0.91.
MRK PEG Ratio Chart
MRK Average PEG Ratio Chart
MRK Current vs Average PEG Ratio Chart
MRK PEG Ratio Metrics
PEG RATIO
1.81
PEG RATIO AVG TTM
0.91
PEG RATIO AVG 3Y
1.19
PEG RATIO AVG 5Y
0.93
PEG RATIO AVG 10Y
0.81
PEG RATIO AVG 15Y
0.86
PEG RATIO AVG 20Y
0.82
CURRENT VS TTM AVG
+100.00%
CURRENT VS 3Y AVG
+52.53%
CURRENT VS 5Y AVG
+94.10%
CURRENT VS 10Y AVG
+124.25%
CURRENT VS 15Y AVG
+111.20%
CURRENT VS 20Y AVG
+121.47%
MRK Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | $285.24B | 1.81 | 0.91 | 1.19 | 0.93 |
| AstraZeneca PLC (AZN)vs › | $275.88B | 0.14 | 0.14 | 0.20 | 0.23 |
| UnitedHealth Group Incorporated (UNH)vs › | $362.83B | N/A | 1.64 | 1.82 | 1.66 |
| Novo Nordisk A/S (NVO)vs › | $193.39B | 8.17 | 4.72 | 3.08 | 2.83 |
| Amgen Inc. (AMGN)vs › | $184.40B | 0.26 | 0.26 | 2.94 | 2.94 |
| AbbVie Inc. (ABBV)vs › | $390.87B | N/A | 4.69 | 3.25 | 2.98 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $171.57B | 4.51 | 4.57 | 4.57 | 2.77 |
| Gilead Sciences, Inc. (GILD)vs › | $155.75B | 0.01 | 0.01 | 0.38 | 0.25 |
| Abbott Laboratories (ABT)vs › | $154.08B | 3.00 | 0.11 | 0.36 | 0.87 |
| Pfizer Inc. (PFE)vs › | $147.73B | N/A | 0.07 | 0.13 | 0.16 |
Growth-Adjusted Valuation
PEG Ratio
1.81
P/E Ratio
32.5
Merck & Co., Inc. PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. PEG Ratio FAQ
- What is the PEG ratio for Merck & Co., Inc. (MRK)?
- The PEG ratio for MRK stock is 1.81.
- Is Merck & Co., Inc.'s PEG ratio high or low?
- Merck & Co., Inc.'s PEG ratio of 1.81 is 94% above its 4-year average of 0.93, near the high end of its 4-year range (0.00–1.81).
- What is the TTM average PEG ratio for Merck & Co., Inc. (MRK)?
- The TTM average PEG ratio for MRK stock is 0.91.
- What is the 3Y average PEG ratio for Merck & Co., Inc. (MRK)?
- The 3Y average PEG ratio for MRK stock is 1.19.
- What is the 5Y average PEG ratio for Merck & Co., Inc. (MRK)?
- The 5Y average PEG ratio for MRK stock is 0.93.
- What is the 10Y average PEG ratio for Merck & Co., Inc. (MRK)?
- The 10Y average PEG ratio for MRK stock is 0.81.
- What is the 15Y average PEG ratio for Merck & Co., Inc. (MRK)?
- The 15Y average PEG ratio for MRK stock is 0.86.
- What is the 20Y average PEG ratio for Merck & Co., Inc. (MRK)?
- The 20Y average PEG ratio for MRK stock is 0.82.
Merck & Co., Inc. PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2025-12-31 | 1.81 |
| 2024-12-31 | 0.00 |
| 2022-12-31 | 1.75 |
| 2021-12-31 | 0.17 |
| 2019-12-31 | 0.38 |
| 2018-12-31 | 0.20 |
| 2016-12-31 | 1.34 |
| 2014-12-31 | 0.07 |
| 2012-12-31 | 2.82 |
| 2011-12-31 | 0.03 |
| 2009-12-31 | 0.42 |
| 2001-12-31 | 2.37 |
| 2000-12-31 | 1.68 |
| 1999-12-31 | 1.88 |
| 1998-12-31 | 2.11 |
| 1997-12-31 | 1.32 |
| 1996-12-31 | 1.28 |
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis